Tissue Inhibitor of Metalloproteinase 3 (TIMP3) mutations increase glycolytic activity and dysregulate glutamine

Allison Grenell1, Charandeep Singh2, Monisha Raju3

  • 1Case Western Reserve University, Department of Pharmacology, Cleveland, OH, USA; Cole Eye Institute, Department of Ophthalmic Research, Cleveland Clinic Foundation, Cleveland, OH, USA.

Molecular Metabolism
|July 24, 2024
PubMed
Abstract

Insights

Mutations in Tissue Inhibitor of Metalloproteinases 3 (TIMP3) cause Sorsby's Fundus Dystrophy (SFD). This study reveals that SFD involves RPE metabolic dysfunction, specifically altered glucose metabolism, suggesting it as a therapeutic target.

Area of Science:

  • Ophthalmology
  • Genetics
  • Cell Biology

Background:

  • Sorsby's Fundus Dystrophy (SFD) is a rare, inherited macular degeneration caused by mutations in Tissue Inhibitor of Metalloproteinases 3 (TIMP3).
  • Retinal Pigment Epithelial (RPE) cells are crucial for retinal health and nutrient supply, and their metabolic dysfunction is implicated in retinal degenerations.
  • The role of RPE metabolic dysfunction in SFD pathogenesis remained unclear.

Purpose of the Study:

  • To investigate whether RPE metabolic dysfunction contributes to the pathogenesis of Sorsby's Fundus Dystrophy.
  • To identify specific metabolic pathways affected in SFD.

Main Methods:

  • Quantitative proteomics was performed on RPE from mice with a TIMP3 S179C mutation (SFD-causative).
  • Gene Ontology analysis (g:profiler, PANTHER) identified enriched pathways.
  • Metabolic activity was assessed in human ARPE-19 cells and patient-derived iRPE cells expressing mutant TIMP3 using isotopic tracing ([U-13C6] glucose, [U-13C5] glutamine) and GC/MS.

Main Results:

  • Proteomics revealed dysregulated glycolysis and glucose metabolism in mutant TIMP3 RPE.
  • Isotopic tracing demonstrated enhanced glucose utilization and glycolytic activity in cells with mutant TIMP3.
  • SFD iRPE cells showed increased glucose contribution to glycolysis and the TCA cycle, with altered malic enzyme activity.

Conclusions:

  • RPE glucose metabolism is significantly dysregulated in Sorsby's Fundus Dystrophy.
  • These metabolic alterations may be a common feature in retinal degenerative diseases.
  • Targeting RPE cellular metabolism presents a potential therapeutic strategy for SFD.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
151
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K